Quality & complianceOfficial

DKMA flags Vimpat 100 mg supply problems from November 2026 amid higher demand

🇩🇰 DKMA · Wed 28 Oct 2026

The Danish Medicines Agency expects UCB Nordic's lacosamide 100 mg film-coated tablets to be affected from early November 2026 until early February 2027, citing increased sales and demand.

The Danish Medicines Agency (Lægemiddelstyrelsen, DKMA) has published a notice warning of upcoming supply problems for Vimpat 100 mg film-coated tablets from UCB Nordic A/S. The product contains the antiepileptic active substance lacosamide (ATC code N03AX18).

According to the agency, the expected period of disruption runs from the start of November 2026 to the start of February 2027, roughly three months. The notice was first posted on 19 October 2026 and updated on 28 October 2026.

DKMA gives the cause as increased sales and demand. The notice does not say which strengths or pack sizes beyond the 100 mg tablets are affected, and it does not describe alternative products or mitigation measures.

The agency directs questions about the current status to the company. The notice sits within DKMA's section on announcements about medicine supply, which is part of its wider work on shortages of medicines.

What it means for your team

  • Supply-chain and shortage-management teams in Denmark should plan for possible 100 mg tablet gaps between November 2026 and February 2027, and check current status directly with UCB Nordic.
  • The notice names demand growth, not a quality or manufacturing issue, as the cause.
  • DKMA does not list alternatives in this notice, so market-access and medical teams may need to look at other strengths or presentations through their usual channels.
  • The dates are expected rather than confirmed and may change, as the notice has already been updated once.

Official source: DKMA ↗

Article written by VigiEye from the official source (DKMA). AI-assisted; check the source before acting.

More Quality & compliance All →